These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

127 related items for PubMed ID: 32601017

  • 1. Inhibitory effects of sesamin on CYP2C9-dependent 7-hydroxylation of S-warfarin.
    Fujii M, Yasuda K, Sakaki T.
    Drug Metab Pharmacokinet; 2020 Aug; 35(4):368-373. PubMed ID: 32601017
    [Abstract] [Full Text] [Related]

  • 2. 7-Hydroxylation of warfarin is strongly inhibited by sesamin, but not by episesamin, caffeic and ferulic acids in human hepatic microsomes.
    Pilipenko N, Rasmussen MK, Doran O, Zamaratskaia G.
    Food Chem Toxicol; 2018 Mar; 113():14-18. PubMed ID: 29353070
    [Abstract] [Full Text] [Related]

  • 3. Comparison of metabolism of sesamin and episesamin by drug-metabolizing enzymes in human liver.
    Yasuda K, Ikushiro S, Wakayama S, Itoh T, Yamamoto K, Kamakura M, Munetsuna E, Ohta M, Sakaki T.
    Drug Metab Dispos; 2012 Oct; 40(10):1917-26. PubMed ID: 22752007
    [Abstract] [Full Text] [Related]

  • 4. In vitro inhibition of CYP2C9-mediated warfarin 7-hydroxylation by iguratimod: possible mechanism of iguratimod-warfarin interaction.
    Yamaori S, Takami K, Shiozawa A, Sakuyama K, Matsuzawa N, Ohmori S.
    Biol Pharm Bull; 2015 Oct; 38(3):441-7. PubMed ID: 25757926
    [Abstract] [Full Text] [Related]

  • 5. Effect of glimepiride and glibenclamide on S-warfarin 7-hydroxylation by human liver microsomes, recombinant human CYP2C9.1 and CYP2C9.3.
    Iwakawa S, Miyashita K, Hashimoto Y, Kuroda T.
    Biol Pharm Bull; 2006 Sep; 29(9):1983-5. PubMed ID: 16946524
    [Abstract] [Full Text] [Related]

  • 6. Warfarin analog inhibition of human CYP2C9-catalyzed S-warfarin 7-hydroxylation.
    Zhang ZY, Kerr J, Wexler RS, Li HY, Robinson AJ, Harlow PP, Kaminsky LS.
    Thromb Res; 1997 Nov 15; 88(4):389-98. PubMed ID: 9526963
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Metabolism of sesamin by cytochrome P450 in human liver microsomes.
    Yasuda K, Ikushiro S, Kamakura M, Ohta M, Sakaki T.
    Drug Metab Dispos; 2010 Dec 15; 38(12):2117-23. PubMed ID: 20851877
    [Abstract] [Full Text] [Related]

  • 9. Roles of two allelic variants (Arg144Cys and Ile359Leu) of cytochrome P4502C9 in the oxidation of tolbutamide and warfarin by human liver microsomes.
    Yamazaki H, Inoue K, Shimada T.
    Xenobiotica; 1998 Feb 15; 28(2):103-15. PubMed ID: 9522436
    [Abstract] [Full Text] [Related]

  • 10. Hydroxywarfarin metabolites potently inhibit CYP2C9 metabolism of S-warfarin.
    Jones DR, Kim SY, Guderyon M, Yun CH, Moran JH, Miller GP.
    Chem Res Toxicol; 2010 May 17; 23(5):939-45. PubMed ID: 20429590
    [Abstract] [Full Text] [Related]

  • 11. Comparison in the in vitro inhibitory effects of major phytocannabinoids and polycyclic aromatic hydrocarbons contained in marijuana smoke on cytochrome P450 2C9 activity.
    Yamaori S, Koeda K, Kushihara M, Hada Y, Yamamoto I, Watanabe K.
    Drug Metab Pharmacokinet; 2012 May 17; 27(3):294-300. PubMed ID: 22166891
    [Abstract] [Full Text] [Related]

  • 12. Tolbutamide hydroxylation by hepatic microsomes from Atlantic salmon (Salmo salar L.).
    Vestergren AS, Zlabek V, Pickova J, Zamaratskaia G.
    Mol Biol Rep; 2012 Jun 17; 39(6):6867-73. PubMed ID: 22311023
    [Abstract] [Full Text] [Related]

  • 13. Inhibition of CYP2C9 by selective serotonin reuptake inhibitors: in vitro studies with tolbutamide and (S)-warfarin using human liver microsomes.
    Hemeryck A, De Vriendt C, Belpaire FM.
    Eur J Clin Pharmacol; 1999 Feb 17; 54(12):947-51. PubMed ID: 10192756
    [Abstract] [Full Text] [Related]

  • 14. Effect of ethanol on S-warfarin and diclofenac metabolism by recombinant human CYP2C9.1.
    Tatsumi A, Ikegami Y, Morii R, Sugiyama M, Kadobayashi M, Iwakawa S.
    Biol Pharm Bull; 2009 Mar 17; 32(3):517-9. PubMed ID: 19252308
    [Abstract] [Full Text] [Related]

  • 15. Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes.
    Yamazaki H, Shimada T.
    Arch Biochem Biophys; 1997 Oct 01; 346(1):161-9. PubMed ID: 9328296
    [Abstract] [Full Text] [Related]

  • 16. Characterization of inhibition kinetics of (S)-warfarin hydroxylation by noscapine: implications in warfarin therapy.
    Zhang N, Seguin RP, Kunze KL, Zhang YY, Jeong H.
    Drug Metab Dispos; 2013 Dec 01; 41(12):2114-23. PubMed ID: 24046330
    [Abstract] [Full Text] [Related]

  • 17. [Metabolism of Sesamin and Drug-Sesamin Interaction].
    Sakaki T, Yasuda K, Nishikawa M, Ikushiro S.
    Yakugaku Zasshi; 2018 Dec 01; 138(3):357-363. PubMed ID: 29503429
    [Abstract] [Full Text] [Related]

  • 18. Formation of (R)-8-hydroxywarfarin in human liver microsomes. A new metabolic marker for the (S)-mephenytoin hydroxylase, P4502C19.
    Wienkers LC, Wurden CJ, Storch E, Kunze KL, Rettie AE, Trager WF.
    Drug Metab Dispos; 1996 May 01; 24(5):610-4. PubMed ID: 8723744
    [Abstract] [Full Text] [Related]

  • 19. In vitro inhibition of 7-ethoxyresorufin-O-deethylase (EROD) and p-nitrophenol hydroxylase (PNPH) activities by sesamin in hepatic microsomes from two fish species.
    Wagner L, Zlabek V, Trattner S, Zamaratskaia G.
    Mol Biol Rep; 2013 Jan 01; 40(1):457-62. PubMed ID: 23065221
    [Abstract] [Full Text] [Related]

  • 20. Inhibitory Effects of Dimethyllirioresinol, Epimagnolin A, Eudesmin, Fargesin, and Magnolin on Cytochrome P450 Enzyme Activities in Human Liver Microsomes.
    Kim JH, Kwon SS, Jeong HU, Lee HS.
    Int J Mol Sci; 2017 May 01; 18(5):. PubMed ID: 28468305
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.